Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 64 | 2023 | 1173 | 12.280 |
Why?
|
| Early Detection of Cancer | 38 | 2022 | 454 | 8.290 |
Why?
|
| Solitary Pulmonary Nodule | 12 | 2020 | 77 | 3.560 |
Why?
|
| Multiple Pulmonary Nodules | 9 | 2020 | 41 | 3.470 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2020 | 300 | 2.770 |
Why?
|
| Mass Screening | 17 | 2022 | 843 | 2.650 |
Why?
|
| Tomography, X-Ray Computed | 27 | 2022 | 2324 | 1.980 |
Why?
|
| Bronchoscopy | 11 | 2021 | 147 | 1.980 |
Why?
|
| Mediastinum | 5 | 2021 | 39 | 1.900 |
Why?
|
| Decision Making | 6 | 2020 | 410 | 1.610 |
Why?
|
| Lung | 10 | 2023 | 849 | 1.480 |
Why?
|
| Patient Participation | 4 | 2020 | 146 | 1.430 |
Why?
|
| Pneumonectomy | 3 | 2015 | 79 | 1.390 |
Why?
|
| Smoking | 13 | 2022 | 1452 | 1.360 |
Why?
|
| Pulmonologists | 2 | 2019 | 5 | 1.240 |
Why?
|
| Endosonography | 6 | 2021 | 177 | 1.220 |
Why?
|
| Smoking Cessation | 9 | 2022 | 1034 | 1.200 |
Why?
|
| Lymph Nodes | 5 | 2021 | 258 | 1.130 |
Why?
|
| Humans | 77 | 2023 | 68618 | 1.040 |
Why?
|
| Neoplasm Staging | 12 | 2021 | 800 | 1.020 |
Why?
|
| Tobacco Products | 3 | 2022 | 234 | 0.890 |
Why?
|
| United States | 24 | 2023 | 7367 | 0.860 |
Why?
|
| Male | 42 | 2022 | 37321 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 504 | 0.810 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2021 | 16 | 0.790 |
Why?
|
| Tobacco Use Disorder | 3 | 2022 | 432 | 0.770 |
Why?
|
| Proteomics | 2 | 2020 | 246 | 0.760 |
Why?
|
| Aged | 27 | 2022 | 14862 | 0.750 |
Why?
|
| Fluoroscopy | 2 | 2020 | 152 | 0.750 |
Why?
|
| Female | 40 | 2022 | 38074 | 0.740 |
Why?
|
| Incidental Findings | 3 | 2017 | 42 | 0.690 |
Why?
|
| Veterans | 3 | 2018 | 904 | 0.690 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 508 | 0.680 |
Why?
|
| Patient Care | 1 | 2019 | 61 | 0.630 |
Why?
|
| Surgeons | 1 | 2019 | 68 | 0.620 |
Why?
|
| Disease Management | 2 | 2019 | 248 | 0.610 |
Why?
|
| Health Personnel | 2 | 2020 | 286 | 0.600 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 119 | 0.600 |
Why?
|
| Patient Compliance | 1 | 2020 | 402 | 0.590 |
Why?
|
| Middle Aged | 26 | 2020 | 21147 | 0.580 |
Why?
|
| Communication | 2 | 2023 | 329 | 0.580 |
Why?
|
| Clinical Competence | 4 | 2017 | 657 | 0.580 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 107 | 0.570 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 261 | 0.560 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 136 | 0.530 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 629 | 0.530 |
Why?
|
| Risk Assessment | 8 | 2020 | 2007 | 0.530 |
Why?
|
| Cohort Studies | 8 | 2022 | 2358 | 0.520 |
Why?
|
| Radiography, Thoracic | 6 | 2020 | 99 | 0.520 |
Why?
|
| Guideline Adherence | 2 | 2017 | 287 | 0.500 |
Why?
|
| Sputum | 1 | 2015 | 51 | 0.500 |
Why?
|
| Tomography, Spiral Computed | 1 | 2015 | 57 | 0.500 |
Why?
|
| Risk Factors | 10 | 2020 | 5731 | 0.490 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 207 | 0.460 |
Why?
|
| Pain Management | 1 | 2015 | 186 | 0.460 |
Why?
|
| Physicians | 1 | 2017 | 324 | 0.450 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 214 | 0.450 |
Why?
|
| Culture | 1 | 2013 | 75 | 0.450 |
Why?
|
| Neoplasms | 3 | 2021 | 1667 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 772 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 468 | 0.410 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 127 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 104 | 0.390 |
Why?
|
| Patient Selection | 5 | 2018 | 592 | 0.390 |
Why?
|
| Positron-Emission Tomography | 5 | 2015 | 160 | 0.390 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 2800 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 322 | 0.370 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 274 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 767 | 0.370 |
Why?
|
| Attitude to Health | 1 | 2013 | 403 | 0.370 |
Why?
|
| Precision Medicine | 1 | 2011 | 111 | 0.360 |
Why?
|
| Critical Care | 1 | 2013 | 263 | 0.360 |
Why?
|
| ErbB Receptors | 1 | 2011 | 239 | 0.350 |
Why?
|
| Survival Rate | 4 | 2020 | 1056 | 0.350 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 17 | 0.330 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2021 | 38 | 0.330 |
Why?
|
| Lung Diseases | 3 | 2017 | 175 | 0.330 |
Why?
|
| Preventive Health Services | 2 | 2022 | 86 | 0.330 |
Why?
|
| Probability | 4 | 2017 | 245 | 0.320 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 201 | 0.310 |
Why?
|
| Incidence | 4 | 2020 | 1603 | 0.310 |
Why?
|
| Pandemics | 3 | 2020 | 352 | 0.310 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 4848 | 0.290 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 49 | 0.290 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 0.290 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 0.290 |
Why?
|
| Smokers | 2 | 2020 | 200 | 0.280 |
Why?
|
| Pulmonary Medicine | 2 | 2017 | 31 | 0.260 |
Why?
|
| Societies, Medical | 4 | 2023 | 403 | 0.230 |
Why?
|
| Prospective Studies | 8 | 2020 | 3705 | 0.230 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1140 | 0.220 |
Why?
|
| Adult | 14 | 2022 | 21403 | 0.220 |
Why?
|
| Veterans Health | 3 | 2018 | 62 | 0.210 |
Why?
|
| Mediastinal Diseases | 2 | 2013 | 15 | 0.200 |
Why?
|
| Data Collection | 2 | 2013 | 420 | 0.200 |
Why?
|
| False Positive Reactions | 3 | 2018 | 95 | 0.200 |
Why?
|
| Radiation Dosage | 3 | 2019 | 419 | 0.190 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 307 | 0.190 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 109 | 0.190 |
Why?
|
| Multimodal Imaging | 2 | 2018 | 62 | 0.180 |
Why?
|
| Health Communication | 1 | 2020 | 19 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2020 | 132 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2020 | 238 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3259 | 0.170 |
Why?
|
| Midazolam | 1 | 2018 | 46 | 0.160 |
Why?
|
| Counseling | 2 | 2020 | 280 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 848 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 442 | 0.160 |
Why?
|
| Conscious Sedation | 1 | 2018 | 61 | 0.150 |
Why?
|
| Benzodiazepines | 1 | 2018 | 130 | 0.150 |
Why?
|
| Mediastinoscopy | 1 | 2017 | 13 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7277 | 0.150 |
Why?
|
| Electromagnetic Phenomena | 1 | 2017 | 25 | 0.150 |
Why?
|
| Radiography | 2 | 2015 | 572 | 0.150 |
Why?
|
| Trees | 1 | 2017 | 8 | 0.140 |
Why?
|
| Grounded Theory | 1 | 2016 | 20 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Risk | 1 | 2017 | 563 | 0.130 |
Why?
|
| Pancoast Syndrome | 1 | 2015 | 2 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 392 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1864 | 0.130 |
Why?
|
| Focus Groups | 1 | 2016 | 247 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 307 | 0.130 |
Why?
|
| Prevalence | 2 | 2020 | 1619 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2077 | 0.130 |
Why?
|
| Mortality | 1 | 2016 | 163 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2016 | 369 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 129 | 0.120 |
Why?
|
| Primary Health Care | 2 | 2017 | 703 | 0.120 |
Why?
|
| Bronchi | 1 | 2014 | 59 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 74 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 81 | 0.120 |
Why?
|
| Comorbidity | 1 | 2018 | 1426 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.110 |
Why?
|
| Bronchoscopes | 1 | 2013 | 9 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 792 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2014 | 66 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 27 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2017 | 326 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1330 | 0.110 |
Why?
|
| Curriculum | 1 | 2017 | 575 | 0.110 |
Why?
|
| Puerto Rico | 1 | 2013 | 31 | 0.110 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2013 | 100 | 0.110 |
Why?
|
| Patient Simulation | 1 | 2013 | 64 | 0.100 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 172 | 0.100 |
Why?
|
| Self Report | 1 | 2013 | 371 | 0.100 |
Why?
|
| Health Status | 1 | 2013 | 429 | 0.090 |
Why?
|
| Tobacco | 2 | 2022 | 161 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 170 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 504 | 0.090 |
Why?
|
| Lymphocele | 1 | 2009 | 3 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.080 |
Why?
|
| Consensus | 2 | 2020 | 211 | 0.080 |
Why?
|
| Eligibility Determination | 2 | 2020 | 31 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 475 | 0.080 |
Why?
|
| Betacoronavirus | 2 | 2020 | 116 | 0.080 |
Why?
|
| Endoscopy | 1 | 2012 | 464 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 931 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2017 | 502 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2014 | 7029 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2017 | 413 | 0.050 |
Why?
|
| Bupropion | 1 | 2022 | 63 | 0.050 |
Why?
|
| Research | 1 | 2023 | 214 | 0.050 |
Why?
|
| Prognosis | 2 | 2018 | 2093 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1465 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 2020 | 18 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 1420 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Social Class | 1 | 2020 | 127 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2020 | 99 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 99 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 197 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 302 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 729 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 96 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.040 |
Why?
|
| Functional Residual Capacity | 1 | 2017 | 3 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.040 |
Why?
|
| Breath Holding | 1 | 2017 | 8 | 0.040 |
Why?
|
| Forests | 1 | 2017 | 9 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2017 | 55 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 284 | 0.040 |
Why?
|
| Respiration | 1 | 2017 | 91 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2017 | 27 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.040 |
Why?
|
| SEER Program | 1 | 2017 | 153 | 0.030 |
Why?
|
| Communication Barriers | 1 | 2017 | 48 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 114 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2017 | 230 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 333 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2014 | 7 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1738 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 76 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 136 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 114 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 122 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 241 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1753 | 0.030 |
Why?
|
| Mediastinal Neoplasms | 1 | 2013 | 27 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 21 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2013 | 40 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| Patient Preference | 1 | 2013 | 57 | 0.030 |
Why?
|
| Lymphoma | 1 | 2013 | 116 | 0.030 |
Why?
|
| Education, Medical | 1 | 2014 | 147 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 453 | 0.030 |
Why?
|
| Equipment Design | 1 | 2013 | 500 | 0.030 |
Why?
|
| South Carolina | 1 | 2018 | 2752 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 652 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 706 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 191 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 369 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 84 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 120 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 880 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 332 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 5717 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 2891 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.020 |
Why?
|
| Child | 1 | 2013 | 6405 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 8912 | 0.010 |
Why?
|